TNDM News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

TN

Mkt Cap

$1.13B

Volume

1.34M

Next Earnings

November 5th

Loading chart

TN

TNDMTandem Diabetes Care, Inc.

TNDM

Pay with—

Available Balance0.00

TN

Mkt Cap

$1.15B

Volume

1.34M

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Is it the Right Time to Hold TNDM Stock in Your Portfolio?Tandem Diabetes Care (TNDM) is expanding its product portfolio with new tubeless pump technology and next-generation closed-loop systems while driving international sales growth through direct commercialization. However, the company faces headwinds from intense competitive pressure, GLP-1 drug adoption impacts on insulin therapy demand, and supply chain constraints that are expected to persist through 2026.Zacks Investment Research · Oct 9, 2026

Reasons to Retain Tandem Diabetes Stock in Your Portfolio NowTandem Diabetes (TNDM) is positioned for growth with its expanding product roadmap including the Mobi tubeless pump, new CGM integrations, and AIDANET closed-loop program. The company's pay-as-you-go reimbursement model aims to lower upfront barriers and boost recurring supply revenue. However, macroeconomic pressures, reimbursement sensitivity, competitive threats, and the impact of GLP-1 drugs on insulin therapy demand pose significant headwinds to sustained profitability.Zacks Investment Research · Sep 9, 2026

Aging Population Drives Healthcare Growth: Stocks to WatchThe global aging population is reshaping healthcare investment opportunities, with the geriatric care services market projected to grow from $1.24 trillion in 2025 to $2.16 trillion by 2034. Healthcare companies are capitalizing on this demographic shift through innovations in diabetes care, cardiovascular treatments, robotic surgery, and digital health solutions. Key players like AbbVie, Tandem Diabetes Care, Amgen, Stryker, and Boston Scientific are advancing AI-enabled technologies and specialized treatments for age-related conditions.Zacks Investment Research · Aug 31, 2026

FDA Flags High-Risk Recall For Tandem Diabetes Mobi PumpsThe FDA has classified a Class I recall for Tandem Diabetes Care's Mobi insulin pumps due to a potential 'false motor failure' detection that could halt insulin delivery. Affected devices running software versions 7.6.0.1, 7.6.0.3, and 7.7.0.1 must be updated to version 7.9.0.2. As of November 4, 2025, four serious injuries have been reported with no deaths. Users are advised to have backup insulin delivery methods ready.Benzinga · Apr 24, 2026

Tandem Diabetes Care, Inc. Investigated by the Portnoy Law FirmThe Portnoy Law Firm has initiated a securities fraud investigation into Tandem Diabetes Care following a 19.9% stock price decline on August 7, 2025. The drop was triggered by the company's disclosure of a malfunction in its insulin pumps that could discontinue insulin delivery and cause hyperglycemia. Tandem had notified affected customers before the public market disclosure.GlobeNewswire Inc. · Mar 27, 2026

[Latest] Global Intravenous Infusion Pump Market Size/Share Worth USD 14.02 Billion by 2035 at a 7.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)The global intravenous infusion pump market was valued at USD 6.72 billion in 2025 and is projected to reach USD 14.02 billion by 2035, growing at a CAGR of 7.6%. Growth is driven by increasing chronic diseases, aging populations, technological advancements in smart pumps, and rising demand for precise medication delivery in hospitals and home care settings.GlobeNewswire Inc. · Mar 9, 2026

Tandem Diabetes Shares Rise 33% On Earnings Beat, Margin Expansion, Growth OutlookTandem Diabetes Care (NASDAQ: TNDM) shares surged 33-37% following strong Q4 earnings results that beat expectations with adjusted loss of $0.01 vs. consensus loss of $0.08, and sales of $290.4M exceeding the $277M consensus. The company reported significant margin expansion with adjusted gross profit jumping from 51% to 58%, and adjusted operating profit of $8.3M versus a $30.2M loss year-ago. For 2026, the company forecasts sales of $1.065-$1.085B and expects 5-6% adjusted EBITDA margins, though slightly below consensus expectations. Management highlighted plans for double-digit pump shipment growth and a new pay-as-you-go model to improve profitability.Benzinga · Feb 20, 2026

TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your RightsThe Rosen Law Firm is investigating potential securities claims on behalf of Tandem Diabetes Care shareholders following the company's August 7, 2025 announcement of a voluntary medical device correction for select t:slim X2 insulin pumps due to a speaker-related issue that could discontinue insulin delivery. The stock fell 19.9% on the news. The firm is preparing a class action lawsuit to recover investor losses.GlobeNewswire Inc. · Feb 8, 2026

TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your RightsThe Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care (TNDM) following the company's August 7, 2025 announcement of a voluntary medical device correction for select t:slim X2 insulin pumps due to a speaker-related issue that could discontinue insulin delivery. The stock fell 19.9% on the news. The firm is preparing a class action lawsuit to recover investor losses.GlobeNewswire Inc. · Feb 6, 2026

TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your RightsThe Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. following the company's August 7, 2025 announcement of a voluntary medical device correction for select t:slim X2 insulin pumps due to a speaker-related issue that could discontinue insulin delivery. The stock fell 19.9% on the announcement. Investors who purchased TNDM securities may be eligible for compensation through a class action lawsuit.GlobeNewswire Inc. · Jan 30, 2026

to start trading

TN

TNDMTandem Diabetes Care, Inc.

TNDM

Pay with—

Available Balance0.00

Your PositionYou don't own any TNDM yet.

Related Tickers

Earnings